Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sales, wholesaling, and retailing of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. More Details
+ 1 more risk
Slightly overvalued with questionable track record.
Share Price & News
How has Lavipharm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LAVI is more volatile than 90% of Greek stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LAVI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Greek stocks.
7 Day Return
1 Year Return
Return vs Industry: LAVI exceeded the Greek Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: LAVI exceeded the Greek Market which returned -8.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Lavipharm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StWe're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory Profitability
6 months ago | Simply Wall StHere's Why We Don't Think Lavipharm's (ATH:LAVI) Statutory Earnings Reflect Its Underlying Earnings Potential
9 months ago | Simply Wall StShould You Rely On Lavipharm's (ATH:LAVI) Earnings Growth?
Is Lavipharm undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: LAVI (€0.47) is trading above our estimate of fair value (€0.13)
Significantly Below Fair Value: LAVI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LAVI is good value based on its PE Ratio (11x) compared to the European Pharmaceuticals industry average (24.3x).
PE vs Market: LAVI is good value based on its PE Ratio (11x) compared to the Greek market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LAVI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LAVI has negative assets, so we can't compare its PB Ratio to the XE Pharmaceuticals industry average.
How is Lavipharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lavipharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Lavipharm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LAVI has high quality earnings.
Growing Profit Margin: LAVI's current net profit margins (5.8%) are lower than last year (15.9%).
Past Earnings Growth Analysis
Earnings Trend: LAVI has become profitable over the past 5 years, growing earnings by 9.8% per year.
Accelerating Growth: LAVI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LAVI had negative earnings growth (-59.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.9%).
Return on Equity
High ROE: LAVI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Lavipharm's financial position?
Financial Position Analysis
Short Term Liabilities: LAVI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: LAVI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: LAVI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: LAVI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: LAVI's debt is not well covered by operating cash flow (10.5%).
Interest Coverage: LAVI's interest payments on its debt are not well covered by EBIT (2.8x coverage).
What is Lavipharm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LAVI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LAVI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LAVI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LAVI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LAVI's dividend in 3 years as they are not forecast to pay a notable one for the Greek market.
How experienced are the management team and are they aligned to shareholders interests?
Lavipharm has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lavipharm S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Lavipharm S.A.
- Ticker: LAVI
- Exchange: ATSE
- Founded: 1911
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €23.804m
- Shares outstanding: 51.08m
- Website: https://www.lavipharm.gr
Number of Employees
- Lavipharm S.A.
- Agias Marinas Street
- PO Box 59
- 190 02
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sales, wholesaling, and retailing of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 16:21|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.